With the rapidly evolving technology, digital health is transforming healthcare, emerging as a promising solution to reduce rising healthcare costs and improve patient care. According to ResearchAndMarkets.com, the global digital health technologies market is set to grow from USD 174.7 billion in 2021 to USD 384.8 billion by 2026. Digital health technologies are increasingly more patient-centric as devices are made available for home use by patients. This usage model provides more frequent patient data, and enables early interventions based both on daily monitoring of data by clinicians, together with well-constructed software algorithms detecting early signs of health exacerbations.
With this transformation comes challenges of user adoption and adherence. Patients with compromised health often have cognitive impairments and may be overwhelmed by technology used in the devices, such as Bluetooth, and may struggle with adoption and/or adherence to new digital health technologies. When this happens, it can negatively impact the value and efficacy of these technologies to patient outcomes and healthcare costs, affecting data quality, data validity and data reliability.
So what can be done to combat user adoption and adherence challenges?
To combat user adoption and adherence challenges, it is necessary to incorporate the evaluation of Human Factors, also referred to as usability engineering, positioning the patient at the centre of the digital health technology development. It is important to understand the intended patient’s needs and related variables such as patient behaviour, physical and cognitive abilities, technological abilities, accessibility, mobility, anticipated operating environments and other demographic characteristics. This includes gaining an understanding of how a user may perceive/interpret information, how a user utilizes the software within the use environment, how input is received from a user and how the software responds and provides feedback to the user as a result of actions taken by the user. Gaining understanding of human factors enables mitigation of potential use error risks, including risks related to technology adoption and adherence, throughout device design and development.
For example, if a patient has dexterity difficulties, it may be challenging for the patient to enter data via a keyboard so your device may need to incorporate an alternate method of data entry to mitigate this risk. Another example would be if your patient has cognitive issues, it may mean that the patient could forget to use the device so you may need to incorporate some form of reminder mechanism. Language proficiency could be another concern as vocabularies differ between age groups and other demographic characteristics, so your device needs to consider this in all types of labelling.
Instructions for use need to be clear enough for patients with impairments to understand the steps they need to take when using the device. In the past, most medical devices (https://www.iconplc.com/therapeutics/medical-device) were used by clinicians in hospitals or doctor’s offices; now that this has changed, instructions for use need to target patients without technology or clinical training.
For digital health devices, as for other medical devices, the primary goal of human factors is to minimize use-related hazards and risks during user interface (UI) design in order to enable the intended users to operate the device safely and effectively in the intended use environment. The UI consists of all components of a digital health device with which a user may interact including software UI labelling and user labelling.
It is especially important to assess risk related to the use of the digital health device in advance of performing a clinical investigation for if a digital health device’s usability is lacking, user task completion may be hindered and error-prone. Resulting use errors, especially those that could result in adverse events, can be detrimental to the success of a clinical investigation, even possibly resulting in the need to cancel a clinical investigation. Typically, use-related risk assessment will involve performing a human factors study in advance of the clinical investigation to maximize the likelihood that the digital health device can be used safely and effectively by the patients and/or device users during an investigation.
ICON understands the importance of human factors to the success of digital health and can guide and assist you in your human factors journey with your digital health technology. ICON can help you build human factors into your device development processes throughout your product development life cycle, including the incorporation of use risk evaluation that looks at the many variables that could pose challenges for the patient adopting and adhering to your digital health device.
Contact us to learn more about how we can support your digital health product development needs.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel